MARKET

IMUX

IMUX

Immunic Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

14.20
-0.57
-3.86%
After Hours: 14.57 +0.37 +2.61% 16:32 06/11 EDT
OPEN
14.75
PREV CLOSE
14.77
HIGH
14.93
LOW
14.14
VOLUME
77.26K
TURNOVER
--
52 WEEK HIGH
28.21
52 WEEK LOW
10.39
MARKET CAP
308.84M
P/E (TTM)
-3.7640
1D
5D
1M
3M
1Y
5Y
Immunic, Inc. to Participate in Industry and Investor Conferences in June
/PRNewswire/ -- a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, today announced participation in the following industry and investor con...
PR Newswire - PRF · 2d ago
Duane Nash Is The Executive Chairman of Immunic, Inc. (NASDAQ:IMUX) And They Just Picked Up 40% More Shares
Whilst it may not be a huge deal, we thought it was good to see that the Immunic, Inc. ( NASDAQ:IMUX ) Executive...
Simply Wall St. · 05/13 06:01
72 Biggest Movers From Yesterday
Gainers SemiLEDs Corporation (NASDAQ: LEDS) shares surged 85.8% to settle at $10.22 on above-average volume.
Benzinga · 05/07 09:10
10-Q: IMMUNIC, INC.
Edgar Online - (EDG = 10Q, 10K) · 05/06 12:12
Immunic, Inc. Reports First Quarter 2021 Financial Results and Highlights Recent Activity
Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, today announced financial results for the first quarter ended Ma...
PR Newswire · 05/06 11:30
Immunic EPS misses by $0.95
Immunic (IMUX): Q1 GAAP EPS of -$1.63 misses by $0.95.$114.8 Million in Cash and Cash Equivalents Expected to Fund Immunic Into the Second Half of 2022.Press Release
Seekingalpha · 05/06 10:42
BRIEF-Immunic, Inc. Reports Q1 Loss Per Share $1.63
reuters.com · 05/06 10:41
-- Earnings Flash (IMUX) IMMUNIC Posts Q1 Loss $-1.63
MT Newswires · 05/06 06:48
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of IMUX. Analyze the recent business situations of Immunic Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 8 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average IMUX stock price target is 57.50 with a high estimate of 72.00 and a low estimate of 40.00.
EPS
Institutional Holdings
Institutions: 82
Institutional Holdings: 9.46M
% Owned: 43.52%
Shares Outstanding: 21.75M
TypeInstitutionsShares
Increased
18
567.13K
New
6
118.95K
Decreased
23
650.53K
Sold Out
16
465.19K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.29%
Pharmaceuticals & Medical Research
-0.72%
Key Executives
Chairman/Executive Director
Duane Nash
President/Chief Executive Officer/Director
Daniel Vitt
Chief Financial Officer/Chief Accounting Officer/Vice President - Finance
Glenn Whaley
Chief Operating Officer
Manfred Groppel
Chief Scientific Officer
Hella Kohlhof
General Counsel
Inderpal Singh
Other
Andreas Muehler
Independent Director
Tamar Howson
Independent Director
Jorg Neermann
Independent Director
Vincent Ossipow
Independent Director
Barclay Phillips
Independent Director
Jan Van den Bossche
No Data
  • All
  • Financials
  • Insiders
More
About IMUX
Immunic, Inc., formerly Vital Therapies, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on developing oral therapies for the treatment of chronic inflammatory and autoimmune diseases. The Company is developing three small molecule products: IMU-838 is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function. The Company’s lead development program, IMU-838, is in Phase II clinical development for ulcerative colitis and relapsing-remitting multiple sclerosis, with an additional Phase II trial in Crohn’s disease.

Webull offers kinds of Immunic Inc stock information, including NASDAQ:IMUX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IMUX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading IMUX stock methods without spending real money on the virtual paper trading platform.